Quantcast
Home > Quotes > MLNT

Melinta Therapeutics, Inc. Common Stock (MLNT) Quote & Summary Data

MLNT 
$3.1045
*  
0.1245
4.18%
Get MLNT Alerts
*Delayed - data as of May 21, 2019 15:27 ET  -  Find a broker to begin trading MLNT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MLNT Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 3.10 / $ 3.12
1 Year Target
14
Today's High / Low
$ 3.17 / $ 2.67
Share Volume
250,558
50 Day Avg. Daily Volume
515,571
Previous Close
$ 2.98
52 Week High / Low
$ 46 / $ 2.70
Market Cap
36,570,690
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -15.68
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.89

Special Dividend Data

Special Dividend
N/A
Special Dividend Date
Feb. 22, 2019
Special Dividend Payment Date
N/A

Intraday Chart

Shares Traded

Share Volume:
250,558
50 Day Avg. Daily Volume:
515,571

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -15.68

Trading Range

The current last sale of $3.1045 is 14.98% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.17 $ 46
 Low: $ 2.67 $ 2.70

Company Description (as filed with the SEC)

We are a commercial-stage pharmaceutical company focused on developing and commercializing differentiated anti-infectives for the hospital and select non-hospital, or community, settings that address the need for effective treatments for infections due to resistant gram-negative and gram-positive bacteria. We currently market four antibiotics to treat a variety of infections caused by these resistant bacteria. Melinta was formed as a private company in October 2000, and operated using funds from licensing and collaboration agreements, private equity placements and debt until 2017. We received approval for our first drug, Baxdela┬« (delafloxacin), in June 2017. On November 3, 2017, we completed a reverse merger with Cempra, Inc., the result of which the registrant Cempra, Inc. was re-named Melinta Therapeutics, Inc. and we became a publicly-traded company.  ... More ...  



Risk Grade

Where does MLNT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.94
Open Date:
May 21, 2019
Close Price:
$ 2.98
Close Date:
May 20, 2019


Consensus Recommendation

Analyst Info